Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Chemically the active ingredient (semaglutide) can be the same, but the real differences are regulation, manufacturing controls, formulation/device, labeling/dosing, and evidence of safety/effectiveness. Those differences affect reliability, sterility, and legal/insurance coverage.

Key differences explained

• Regulatory status and quality control

  • Wegovy (Novo Nordisk) is an FDA‑approved, manufactured drug product made under strict Good Manufacturing Practices (GMP). Each lot is tested, and the company has ongoing pharmacovigilance.
  • Compounded semaglutide is made by a compounding pharmacy (often from bulk API). It is not FDA‑approved as a finished product, and quality/consistency depends on the pharmacy’s practices. Small compounding shops (503A) are regulated by states and not routinely inspected by the FDA; larger 503B outsourcing facilities have FDA oversight and stricter standards, but many compounding sources do not match branded GMP.

• Formulation and device

  • Wegovy is supplied in a pen injector with fixed concentration, clear labeling, and a specific titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly). The excipients, stability, and device are optimized and validated together.
  • Compounded semaglutide may be provided in vials, prefilled syringes, or nonproprietary cartridges. Concentrations, excipients, shelf life, and device safety features (dose lockout, dosing increments) can vary, increasing risk of dosing errors or decreased stability.

• Safety and sterility

  • Wegovy’s sterility, purity, and absence of contaminants are verified by the manufacturer.
  • Compounded injectables carry a greater risk for contamination, incorrect potency, or impurities unless produced by a properly certified facility and accompanied by sterility and potency testing (COA).

• Evidence and labeling

  • Wegovy’s safety and weight‑loss claims are supported by large phase 3 trials and FDA labeling; clinicians and patients can follow an evidence‑based titration schedule.
  • Compounded versions do not have their own clinical trial data or FDA label; using them means relying on extrapolation from Wegovy data, without the same regulatory oversight.

• Legal, insurance, and reporting

  • Wegovy is covered by some plans and is eligible for adverse‑event reporting to FDA and manufacturer support programs (e.g., Wegovy savings/assistance programs).
  • Compounded products are less likely to be covered by insurance and adverse events may be harder to trace. The FDA has issued warnings in the past about some compounded semaglutide products.

When might people choose compounded semaglutide?

• Cost or lack of access to Wegovy leads some people to seek compounded semaglutide. In theory the active drug is the same and it can be cheaper, but savings come with greater risk unless the product is made and tested by a reputable source.

If you consider compounded semaglutide — what to do

• Prefer FDA‑approved Wegovy if affordability/coverage and supply allow: proven quality, approved dosing, and safety monitoring.
• If you still consider compounded:
  • Use an FDA‑registered 503B outsourcing facility when possible (503B facilities are subject to FDA inspection and CGMP-like standards), or a well‑regarded state‑licensed 503A pharmacy with transparent testing.
  • Ask for documentation: Certificate of Analysis (potency, purity), sterility testing, expiration date, storage instructions, lot number, and chain of custody.
  • Confirm concentration and an exact dosing/titration plan with your prescriber and confirm the device you’ll use (pen vs vial/syringe).
  • Avoid unverified online sellers or international mail‑order vials without documentation.
  • Monitor closely for adverse effects and report problems to your clinician and FDA MedWatch.

Alternatives to discuss with your clinician

• Wegovy (semaglutide, Novo Nordisk) — FDA‑approved for chronic weight management.
• Zepbound (tirzepatide, Eli Lilly) — another recently approved injectable for weight management with different efficacy profile.
• Ozempic (semaglutide, Novo Nordisk) — approved for type 2 diabetes at lower doses; sometimes used off‑label for weight loss under medical supervision.
• Consider lifestyle and behavioral programs and whether patient‑assistance or manufacturer savings programs for Wegovy might reduce your cost.

Bottom line Wegovy gives predictable, tested quality, device reliability, and labeled dosing. Compounded semaglutide can be less expensive but has variable quality, sterility, and legal/insurance issues unless sourced from a reputable, well‑documented compounding facility. Discuss risks, costs, and monitoring with your prescriber before choosing.